Por el fin de la epidemia del VIH y la hepatitis C entre las personas que se inyectan drogas

La Alianza insta a los líderes mundiales a adoptar estrategias basadas en pruebas empíricas y programas fundamentados en el principio de la reducción de daños. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.

The sharing of injecting equipment is driving HIV and hepatitis C (HCV) transmission in many parts of the world. Roughly one third of new HIV infections outside sub-Saharan Africa are the result of unsafe injecting. In 2014 alone, an estimated 110,000 people who inject drugs were newly infected with HIV.

The evidence for the effectiveness of harm reduction interventions is described by UNAIDS as irrefutable and all relevant UN agencies now endorse a harm reduction approach to HIV and drug use. Cost-effective harm reduction programmes that use peer-based outreach and feature clean needle and syringe programmes, opiate substitution therapy and HIV testing and treatment are proven to be effective in reducing HIV transmission and other harms such as hepatitis C transmission, crime rates and overdose deaths.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.